Phase 3 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older (or the legal age of an adult in their country) at the time of the first screening visit
• People whose general health and ability to carry out daily activities meets a certain minimum level — those with a score of 0 or 1 on a standard medical scale, or possibly a score of 2 if the only reason for reduced function is pain or other local symptoms from their myeloma (confirm with trial site)
• People who have received between 1 and 4 previous treatment regimens for multiple myeloma, including the drugs lenalidomide and a proteasome inhibitor, and whose myeloma has come back or stopped responding after their most recent treatment — with additional requirements depending on country (for example, people in Israel, the EU, and the UK must also have previously received a specific type of drug called a CD38 antibody; confirm specific country requirements with trial site)
• People whose myeloma can be measured through standard tests, so that any response to treatment can be tracked
• People whose blood counts, liver, kidneys, heart, and calcium levels are within acceptable ranges within 7 days before being assigned to a treatment group
• People with a life expectancy of at least 6 months

Who may not be able to join:

• People diagnosed with plasma cell leukemia, amyloidosis, Waldenström macroglobulinemia, or POEMS syndrome
• People who have previously been treated with the drugs elotuzumab or pomalidomide
• People who have myeloma that has spread to the brain or the lining around the brain or spinal cord
• People who have received any systemic cancer treatment within either 28 days or 5 half-lives of the study drug (whichever period is shorter) before starting the trial
• People who have had an allogeneic (donor) stem cell transplant within the past 6 months, or a stem cell transplant using their own cells within the past 12 weeks before starting the trial — and those who have had a donor transplant must also have been off all immune-suppressing medications for at least 6 weeks with no signs of graft-versus-host disease
• People who have previously received certain treatments that specifically target a protein called BCMA (note: a particular type of BCMA-targeting drug called an antibody-drug conjugate is allowed — confirm with trial site)
• People with a history of, or known or suspected, a serious brain condition called progressive multifocal leukoencephalopathy (PML), or a history of certain nervous system or movement disorders such as Parkinson's disease
• People who have had an infection serious enough to require hospitalisation or intravenous (drip) antibiotics or antiviral treatment within 2 weeks before starting the trial
• People with an uncontrolled HIV, hepatitis B, or hepatitis C infection, or any other uncontrolled infection (confirm definition with trial site)
• People whose heart pumping function (ejection fraction) is below 40%

Important: Always verify eligibility with the trial site directly before applying.